Though Cigna’s reimbursement medical home model is still in its very early stages, Bhuvana Sagar, MD, national medical director of Cigna Healthcare, explained that discussing value in healthcare and getting back to smarter spending as well as better outcomes for patients should be the focus of all industry stakeholders.
Though Cigna’s reimbursement medical home model is still in its very early stages, Bhuvana Sagar, MD, national medical director of Cigna Healthcare, explained that discussing value in healthcare and getting back to smarter spending as well as better outcomes for patients should be the focus of all industry stakeholders.
Transcript slightly modified)
Will the information generated from the various value frameworks out there influence reimbursement decisions by Cigna?
Definitely, definitely. So what we’re trying to do is we’re trying to get as much data as possible and at this point with our reimbursement medical home models that we have in place—these have been there only for a short time, relatively a short time, probably about a year—we’re still trying to get data, we’re still trying to get experience with the program, providers are still getting used to it, customers are still trying to get used to it.
So once we have more information, we’re definitely going to look and see what works, what doesn’t work and where the greatest impact is going to be and go from there.
Why do you think we need to have the value discussion in healthcare today?
Well with rising healthcare costs and we can’t continue to ignore them at this point and we as a society need to do something to address the cost. You know, the different stakeholders need to be involved in the discussion and we’ve come to a point where we all understand that the fee-for-service system just seems to be adding a lot of that volume without necessarily affecting the quality of care.
So we want to go back to what’s important. We want to have smarter spending, better outcomes for our patients and overall better healthcare for our patients.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More